Trial Profile
An Open-label Rollover Study of ARRY-371797 in Patients With Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Emprumapimod (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions
- Sponsors Array BioPharma; Pfizer
- 13 Sep 2022 Results published in the American Journal of Cardiology
- 15 Feb 2021 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Planned End Date changed from 1 Feb 2022 to 4 Nov 2020.